A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis is a progressive and fatal neurodegenerative disorder 1 associated with survival ranging from a few months to decades (median, 37 to 49 months) 2 – 5 . Known prognostic factors include age at onset, site of onset, duration of weakness, and degree of clinical disability...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 1994-03, Vol.330 (9), p.585-591
Hauptverfasser:	Bensimon, G, Lacomblez, L, Meininger, V
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino acids Amyotrophic lateral sclerosis Asthenia Biological and medical sciences Cancer Disease Drug therapy Expected values Glutamatergic system (aspartate and other excitatory aminoacids) Laboratories Medical imaging Medical prognosis Medical research Medical sciences Motor ability Motor neuron diseases Muscle strength Neurological disorders Neuropharmacology Neurotransmitters. Neurotransmission. Receptors Ostomy Patients Pharmacology. Drug treatments Spasticity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!